Lupus nephritis (LN) is a form of glomerulonephritis that constitutes one of the most severe
organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE). Most …

Lupus nephritis (LN) is a frequent and severe manifestation of SLE. Along the decades, the
epidemiology of LN and its clinical presentation have been changing. However, even …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

Our objective was to update the EULAR recommendations for the management of systemic
lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic …

In the US, approximately 35% of adults with systemic lupus erythematosus (SLE) have
clinical evidence of nephritis at the time of diagnosis, with an estimated total of 50–60 …

Objectives To develop recommendations for the management of adult and paediatric lupus
nephritis (LN). Methods The available evidence was systematically reviewed using the …

Objective AURORA 2 evaluated the long‐term safety, tolerability, and efficacy of voclosporin
compared to placebo in patients with lupus nephritis (LN) receiving an additional two years …

Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages
over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these …

Background Since anecdotal series and small, prospective, controlled trials suggest that
mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are …

Objective: Systemic lupus erythematosus (SLE) is a complex disease with variable
presentations, course and prognosis. We sought to develop evidence-based …